Verified Researcher Certificate
Active ResearchRank profile with at least one indexed scholarly output
RESEARCHER PUBLIC RESEARCH PROFILE● Verified public profile
RRK-A-5078-8239-32
Carlos Eduardo Medina Pech
Works9
Citations797
h-index5
i10-index5
2-year citedness64.33
Mean FWCI*27.33
Top 1%*6
Top 10%*6
ResearchRank IDRRK-A-5078-8239-32
Observed nameCarlos Eduardo Medina Pech
ORCIDNot linked
Current / last-known institutionNot listed
Research topicsDiabetes Treatment and Management · Diabetes Management and Research · Bacterial Infections and Vaccines · SARS-CoV-2 and COVID-19 Research · Herpesvirus Infections and Treatments
Name variantsCarlos E. Medina Pech, Carlos Eduardo Medina Pech, Carlos Medina Pech, Medina Pech, Carlos
FULL PROFILE ANALYSIS
Carlos Eduardo Medina Pech - detailed research intelligence
Identity, scholarly output, impact indicators, affiliations, topics and publication evidence for this ResearchRank record.
Profile typeResearcher
Works9
Citations797
h-index5
i10-index5
Current / last-known affiliationNot listed
ORCIDNot linked
Name variantsCarlos E. Medina Pech, Carlos Eduardo Medina Pech, Carlos Medina Pech, Medina Pech, Carlos
Primary research topics
Diabetes Treatment and ManagementDiabetes Management and ResearchBacterial Infections and VaccinesSARS-CoV-2 and COVID-19 ResearchHerpesvirus Infections and Treatments
Diabetes Treatment and ManagementDiabetes Management and ResearchBacterial Infections and VaccinesSARS-CoV-2 and COVID-19 ResearchHerpesvirus Infections and Treatments
RESEARCH ACHIEVEMENT SNAPSHOT
Evidence-backed profile highlights
This public profile presents scholarly evidence and recognition indicators without displaying certificate prices or checkout controls.
Citation Impact Certificate
At least 100 indexed citations
Public profile: Research metrics and recognition evidence are shown for professional sharing. Commercial pricing and registration controls are intentionally omitted.
Extended publication analytics and related-profile intelligence are loading in the background. The full profile details below remain available even if the live analytics service is temporarily slow.
TOP-CITED OUTPUT
Full profile view · up to 25 leading worksResearch works
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trialArticle · 2017 · 295 citations · Open access · FWCI 34.7813 · Full text ↗
Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week StudyArticle · 2018 · 243 citations · FWCI 24.4502 · Full text ↗
Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV SeasonsArticle · 2024 · 174 citations · Open access · FWCI 52.1742 · Full text ↗
Respiratory Syncytial Virus Prefusion F Protein Vaccine Is Efficacious in Older Adults With Underlying Medical ConditionsArticle · 2023 · 57 citations · Open access · FWCI 11.3373 · Full text ↗
Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 DiabetesArticle · 2026 · 14 citations · Open access · FWCI 69.7424 · Full text ↗
Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 DiabetesArticle · 2026 · 5 citations · Open access · FWCI 24.908 · Full text ↗
Immunological non-inferiority of a new fully liquid presentation of the MenACWY-CRM vaccine to the licensed vaccine: results from a randomized, controlled, observer-blind study in adolescents and young adultsArticle · 2021 · 5 citations · Open access · FWCI 0.7056 · Full text ↗
Safety and immunogenicity of a varicella vaccine without human serum albumin (HSA) versus a HSA-containing formulation administered in the second year of life: a phase III, double-blind, randomized studyArticle · 2019 · 4 citations · Open access · FWCI 0.5707 · Full text ↗